LLY

886.84

-1.79%↓

JNJ

242.4

+0.66%↑

ABBV

212.01

+0.64%↑

NVS

149.19

-0.65%↓

MRK

120.4

+0.94%↑

LLY

886.84

-1.79%↓

JNJ

242.4

+0.66%↑

ABBV

212.01

+0.64%↑

NVS

149.19

-0.65%↓

MRK

120.4

+0.94%↑

LLY

886.84

-1.79%↓

JNJ

242.4

+0.66%↑

ABBV

212.01

+0.64%↑

NVS

149.19

-0.65%↓

MRK

120.4

+0.94%↑

LLY

886.84

-1.79%↓

JNJ

242.4

+0.66%↑

ABBV

212.01

+0.64%↑

NVS

149.19

-0.65%↓

MRK

120.4

+0.94%↑

LLY

886.84

-1.79%↓

JNJ

242.4

+0.66%↑

ABBV

212.01

+0.64%↑

NVS

149.19

-0.65%↓

MRK

120.4

+0.94%↑

Search

Cytek Biosciences Inc

Avatud

SektorTervishoid

4.33 -5.66

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.3

Max

4.65

Põhinäitajad

By Trading Economics

Sissetulek

-39M

-44M

Müük

9.8M

62M

Aktsiakasum

-0

Kasumimarginaal

-70.929

Töötajad

702

EBITDA

4M

-263K

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+35.87% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. mai 2026

Turustatistika

By TradingEconomics

Turukapital

44M

605M

Eelmine avamishind

9.99

Eelmine sulgemishind

4.33

Uudiste sentiment

By Acuity

50%

50%

164 / 349 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Cytek Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

26. märts 2026, 23:43 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over Iran Peace Talks -- Market Talk

26. märts 2026, 23:36 UTC

Market Talk
Uudisväärsed sündmused

Gold Rises Amid Signs of Easing Middle East Tensions -- Market Talk

26. märts 2026, 23:35 UTC

Omandamised, ülevõtmised, äriostud

Pernod Ricard: Confirms Discussions With Brown-Forman

26. märts 2026, 23:29 UTC

Tulu

Haier Smart Home: Company to Finance Share Buybacks Via Internal Funds >600690.SH

26. märts 2026, 23:28 UTC

Tulu

Haier Smart Home Plans A Share Buybacks of CNY3.0B-CNY6.0B >600690.SH

26. märts 2026, 23:28 UTC

Tulu

Haier Smart Home Plans to Increase Payout Ratio to 60% for 2027, 2028 >600690.SH

26. märts 2026, 23:28 UTC

Tulu

Haier Smart Home Plans Cash Dividend Payout Ratio of Up to 58% for 2026 >600690.SH

26. märts 2026, 23:27 UTC

Tulu

Haier Smart Home 2025 Net CNY19.55B Vs. Net CNY18.73B >600690.SH

26. märts 2026, 23:27 UTC

Tulu

Haier Smart Home 2025 Rev CNY302.33B Vs. CNY286.01B >600690.SH

26. märts 2026, 23:08 UTC

Market Talk

Infratil's Investor Day Addresses Data-Center Issues -- Market Talk

26. märts 2026, 23:04 UTC

Omandamised, ülevõtmised, äriostud

Pernod Ricard in Talks to Combine With Jack Daniel's Maker Brown-Forman -- WSJ

26. märts 2026, 23:04 UTC

Omandamised, ülevõtmised, äriostud

Families Behind Pernod, Brown-Forman Would Each Likely Retain Significant Stakes, Source Says -- WSJ

26. märts 2026, 23:04 UTC

Omandamised, ülevõtmised, äriostud

Pernod, Brown-Forman Discussing Mostly Stock Deal, Source Says -- WSJ

26. märts 2026, 23:04 UTC

Omandamised, ülevõtmised, äriostud

Pernod-Brown-Forman Deal Announcement Could Be Weeks Away, Sources Say -- WSJ

26. märts 2026, 23:04 UTC

Omandamised, ülevõtmised, äriostud

Pernod in Deal Talks With Brown-Forman -- WSJ

26. märts 2026, 22:41 UTC

Omandamised, ülevõtmised, äriostud

Brown-Forman: No Agreement Has Been Reached as to Terms of Any Possible Pernod Ricard Transaction

26. märts 2026, 22:41 UTC

Omandamised, ülevõtmised, äriostud

Brown-Forman: Synergies From Contemplated Pernod Ricard Combination Expected to Be Significant

26. märts 2026, 22:26 UTC

Tulu

Jiangxi Copper 2025 Rev CNY544.62B Vs. CNY516.61B >0358.HK

26. märts 2026, 22:26 UTC

Tulu

Jiangxi Copper 2025 Net CNY7.13B Vs. Net CNY6.96B >0358.HK

26. märts 2026, 22:26 UTC

Tulu

Jiangxi Copper Higher Demand For Products Supported Results>0358.HK

26. märts 2026, 22:08 UTC

Tulu

Air China 2025 Loss CNY1.79B Vs. Loss CNY232.56M >0753.HK

26. märts 2026, 22:08 UTC

Tulu

Air China Impairment Loss on Goodwill Weighed on Results>0753.HK

26. märts 2026, 22:08 UTC

Tulu

Air China 2025 Rev CNY171.48B Vs. CNY166.70B >0753.HK

26. märts 2026, 22:07 UTC

Market Talk
Uudisväärsed sündmused

Global Energy Roundup: Market Talk

26. märts 2026, 22:07 UTC

Market Talk
Uudisväärsed sündmused

Open-Pit Gold Miners Most Exposed to High Fuel Prices -- Market Talk

26. märts 2026, 22:00 UTC

Tulu

Tsingtao Brewery 2025 Net CNY4.59B Vs. Net CNY4.34B >0168.HK

26. märts 2026, 22:00 UTC

Tulu

Tsingtao Brewery: Higher Volume Sales of Beer Supported Results>0168.HK

26. märts 2026, 22:00 UTC

Tulu

Tsingtao Brewery 2025 Rev CNY32.47B Vs. CNY32.14B >0168.HK

26. märts 2026, 21:39 UTC

Omandamised, ülevõtmised, äriostud

BlueScope: Sees Early Indications of Strong Interest in Site Adjacent Western Port

26. märts 2026, 21:38 UTC

Omandamised, ülevõtmised, äriostud

BlueScope: Has Begun Expression of Interest Process For 65-Hectare Site Adjacent Western Port

Võrdlus sarnastega

Hinnamuutus

Cytek Biosciences Inc Prognoos

Hinnasiht

By TipRanks

35.87% tõus

12 kuu keskmine prognoos

Keskmine 6.25 USD  35.87%

Kõrge 7.5 USD

Madal 5 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Cytek Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

1

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

3.7 / 3.8Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

164 / 349 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat